TPST

Tempest TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

15%

Probability

Target price

$1.50

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$0.78

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.55

Analysis reference price unavailable

Analysis 2026-08-05 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-05

AI commentary

This is a low-coverage, filing- and company-release-led micro-cap biotech setup. The deterministic prior remains negative, with expected returns of -5.94% over 20 days and -12.47% over 120 days. The new TPST-4003 announcement improves catalyst density, but the evidence remains too early and social, options, short-interest, and analyst-revision signals are unavailable.

RankAlpha Sentiment Codex - 2026-08-05

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystFinancing and dilution remain near-term risksHigh impact

The latest 10-Q contains registered-direct-offering, ATM-program, and warrant disclosures, leaving capital-raising and dilution mechanics important risks for this micro-cap biotech [#SEC-10Q-2026-05-14].

2026-12-31eventTPST-4003 first clinical dosing planned for Q4 2026High impact

Tempest plans an investigator-initiated study of approximately 10 patients with nervous-system autoimmune diseases, with first patient dosing anticipated in Q4 2026 [#PR-EARNINGS-2026-07-15].

2026-12-31catalystTPST-2003 registrational-study preparationHigh impact

Tempest reported interim TPST-2003 results showing a 100% complete-response rate among 15 CAR-T-naive efficacy-evaluable patients, selected Cincinnati Children’s AGCTC as lead manufacturing partner, and targeted a first potentially registrational study later in 2026; the sample remains small and interim [#SEC-8K-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-05 • Updated nightlySource: Internal modelMethodology